Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier España Country of Publication: Spain NLM ID: 8406671 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0210-5705 (Print) Linking ISSN: 02105705 NLM ISO Abbreviation: Gastroenterol Hepatol Subsets: MEDLINE
    • Publication Information:
      Publication: Madrid : Elsevier España
      Original Publication: Barcelona : Ediciones Doyma, SL
    • Subject Terms:
      Non-alcoholic Fatty Liver Disease*/epidemiology ; Non-alcoholic Fatty Liver Disease*/pathology ; Disease Progression* ; Liver Cirrhosis*/etiology ; Liver Cirrhosis*/pathology ; Liver Cirrhosis*/epidemiology; Humans ; Female ; Male ; Middle Aged ; Risk Factors ; Europe/epidemiology ; Adult ; Liver Transplantation ; Aged ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Cohort Studies ; Biopsy
    • Abstract:
      Objective: To better understand drivers of disease progression in non-alcoholic steatohepatitis (NASH), we assessed clinical and sociodemographic markers of fibrosis progression in adults with NASH.
      Patients and Methods: Physician-reported patient demographics and clinical characteristics were utilised from the real-world Global Assessment of the Impact of NASH (GAIN) study. Factors associated with likelihood of fibrosis progression since NASH diagnosis were identified using a logistic regression model.
      Results: Overall, 2349 patients in Europe from the GAIN study were included; mean age was 54.6 years and 41% were women. Significant covariates included age, years since diagnosis, employment status, fibrosis stage at diagnosis, type 2 diabetes mellitus, hypertension, liver transplant and liver biopsy at diagnosis. Risk of progression was 1.16 (95% confidence interval 1.12-1.20; p<0.001) times higher for each additional year since NASH diagnosis and 5.43 (2.68-11.37; p<0.001) times higher when physicians proposed a liver transplant at diagnosis. Compared with full-time employed patients, risk of progression was 1.77 (1.19-2.60; p=0.004) times higher for unemployed patients and 3.16 (1.30-7.63; p=0.010) times higher for those unable to work due to NASH.
      Conclusions: Disease duration, NASH severity and presence of other metabolic comorbidities could help to assess risk of progression in patients with NASH.
      (Copyright © 2023 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.)
    • Contributed Indexing:
      Keywords: Advanced fibrosis; Biopsia hepática; Enfermedad del hígado graso sin alcohol; Esteatohepatitis no alcohólica; Factor de riesgo; Fibrosis avanzada; Liver biopsy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Risk factor
    • Publication Date:
      Date Created: 20231027 Date Completed: 20240430 Latest Revision: 20240516
    • Publication Date:
      20240516
    • Accession Number:
      10.1016/j.gastrohep.2023.10.005
    • Accession Number:
      37890583